2021 Annual Meeting - Radiation/Immunotherapy Combinations – Clinical Highlights and Case Discussion
Immunotherapy has been rapidly integrated into oncology practice across multiple disease types. In many cases, it provides a survival advantage compared with cytotoxic chemotherapy in the metastatic setting; immunotherapy is approved for patients with locally advanced lung cancer following chemoradiation therapy; and immunotherapy is being tested in combination with chemoradiation across multiple other disease types. This session will provide clinicians with an update on clinical trial data relevant to combinations of radiation and immune therapy. Through illustrative cases, we will also go through examples of how the combination is used in clinical practice.
Speakers will highlight potential safety/toxicity concerns regarding combined therapy, questions regarding the sequencing of radiation and immunotherapy, and cases discussing the use of radiation and immunotherapy in the neoadjuvant, adjuvant, oligometastatic and metastatic setting. A good portion of the session will be interactive including case presentations to highlight the potential of radiation immunotherapy combinations already being considered in clinical practice.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents and medical oncologists.
Upon completion of this activity, participants should be able to:
- Identify potential toxicity concerns regarding immunotherapy / radiation combinations.
- Identify settings where radiation/immunotherapy combinations have proven benefit or are being actively evaluated including in the neoadjuvant, adjuvant, oligometastatic and metastatic settings.
- Discuss potential mechanisms behind potential synergy between radiation and immunotherapy as they apply to clinical practice (e.g. the abscopal effect).
- Jonathan D. Schoenfeld, MD, Bringham and Women's Hospital and receives compensation from Merck, BMS, Debiopharm, ACI Clinical, Regeneron, LEK, Immunitas, STIMIT, and Astelas.
- Ezra Cohen, MD, Moores Cancer Center at UC San Diego Health and receives compensation from Merck, Merck Serono, Pfizer and AstraZeneca.
- Florence Kathleen Keane, MD, Partners Healthcare and has investment interest from OncLive and AstraZeneca.
- Andrew Sharabi, MD, PhD, UC San Diego, Moores Cancer Center, Department of Radiation Medicine and Applied Sciences and has investment interest from Toragen Biotechnologies, Pfizer, Varian Medical Systems and AstraZeneca. Dr. Sharabi is a founder of Toragen Biotechnologies and he is a San Diego Center for Precission Immunotherapy Scientific Advisory Committee Member.
- Ramesh Rengan, MD, PhD, FASTRO, FASTRO, University of Washington, Department of Radiation Oncology and has investment interest from IBA and AstraZeneca.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.